Sogaz Medical Center in the Leningrad Region buys a treatment system for cancer ProteusONE for tens of millions of euros

The high-tech multidisciplinary medical complex BMMK (), which is being built in the Leningrad Region "," Sogaz will receive in its equipment cancer the ProteusONE treatment system developed by the company. IBA Worldwide The Russian insurance group announced the conclusion of the relevant agreement on February 14, 2022.

The proton therapy apparatus is ProteusONE equipped with an open gantry, a new pencil beam scanning technology (PBS, minimizes radiation load on healthy tissue), cone-ray computed tomography (CBCT), a suspended device with manual wireless control for convenient patient location and an integrated hardware and software quality control complex.

Sogaz Medical Center in the Leningrad Region buys a treatment system for cancer ProteusONE for tens of millions of euros

The equipment design allows the device to rotate 360 degrees around the patient's body, affecting the tumor anywhere. The message on the IBA website states that the cost of a contract with long-term maintenance can vary in the range of 35-45 million euros.

The contract provides for multi-year operation and maintenance of ProteusONE. It is assumed that its use in the treatment of patients with cancer will begin in the VMMC in 2024.

By mid-February 2022, 31 ProteusONE systems are in operation 12. As specified in the press service of Sogaz, in Russia this is the only compactly placed proton therapy system of the last generation based on the cyclotron.

Anton Ustinov, Chairman of the Management Board of SOGAZ JSC, emphasized that there are no analogues to such a system in a private multidisciplinary medical complex in Russia. He is confident that the introduction of ProteusONE in the VMMC will expand the capabilities of doctors at the medical center and increase "the availability and quality of medical care for cancer patients not only from the Northwest Federal District, but also from other regions of the country."

VMMK will be designed to serve 20 thousand patients per year, and the inpatient cancer center - 3.5 thousand people.^[1]

Notes